CoChat

Long-Acting Neurotensin Synergizes With Liraglutide to Reverse Obesity Through a Melanocortin-Dependent Pathway

Open access
Ratner, Cecilia, He, Zhenyan, Grunddal, Kaare V., Skov, Louise J., Hartmann, Bolette, Zhang, Fa, Feuchtinger, Annette, Bjerregaard, Anette, Christoffersen, Christina, Tschöp, Matthias H., Finan, Brian, DiMarchi, Richard D., Leinninger, Gina M., Williams, Kevin W., Clemmensen, Christoffer, Holst, Birgitte · 2019 · Diabetes
Cited by 40

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Neurotensin (NT), a gut hormone and neuropeptide, increases in circulation after bariatric surgery in rodents and humans and inhibits food intake in mice. However, its potential to treat obesity and the subsequent metabolic dysfunctions have been difficult to assess owing to its short half-life in vivo. Here, we demonstrate that a long-acting, pegylated analog of the NT peptide (P-NT) reduces food intake, body weight, and adiposity in diet-induced obese mice when administered once daily for 6 days. Strikingly, when P-NT was combined with the glucagon-like peptide 1 mimetic liraglutide, the two peptides synergized to reduce food intake and body weight relative to each monotherapy, without inducing a taste aversion. Further, P-NT and liraglutide coadministration improved glycemia and reduced steatohepatitis. Finally, we show that the melanocortin pathway is central for P-NT–induced anorexia and necessary for the full synergistic effect of P-NT and liraglutide combination therapy. Overall, our data suggest that P-NT and liraglutide combination therapy could be an enhanced treatment for obesity with improved tolerability compared with liraglutide monotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db18-1009

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 40

Metadata

Authors
Ratner, C., He, Z., Grunddal, K. V., Skov, L. J., Hartmann, B., Zhang, F., Feuchtinger, A., Bjerregaard, A., Christoffersen, C., Tschöp, M. H., Finan, B., DiMarchi, R. D., Leinninger, G. M., Williams, K. W., Clemmensen, C., & Holst, B.
Venue
Diabetes
Published
2019-04-01
Volume
68
Issue
6
Pages
1329-1340
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2926297340
Cited by
40
References
12
FWCI
3.09
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-Acting Neurotensin Synergizes With Liraglutide to Reverse Obesity Through a Melanocortin-Dependent Pathway. https://app.cochat.ai/papers/10.2337/db18-1009
The paper
Ratner, C., He, Z., Grunddal, K. V., Skov, L. J., Hartmann, B., Zhang, F., Feuchtinger, A., Bjerregaard, A., Christoffersen, C., Tschöp, M. H., Finan, B., DiMarchi, R. D., Leinninger, G. M., Williams, K. W., Clemmensen, C., & Holst, B. (2019). Long-Acting Neurotensin Synergizes With Liraglutide to Reverse Obesity Through a Melanocortin-Dependent Pathway. Diabetes. https://doi.org/10.2337/db18-1009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.